1. Home
  2. VINP vs CSTL Comparison

VINP vs CSTL Comparison

Compare VINP & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

HOLD

Current Price

$9.84

Market Cap

638.8M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$24.71

Market Cap

640.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VINP
CSTL
Founded
2009
2007
Country
Brazil
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
638.8M
640.6M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
VINP
CSTL
Price
$9.84
$24.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$14.00
$45.50
AVG Volume (30 Days)
63.3K
348.7K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
5.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
$18.07
$2.42
Revenue Next Year
$12.74
$12.69
P/E Ratio
$24.41
N/A
Revenue Growth
N/A
3.66
52 Week Low
$9.20
$14.59
52 Week High
$13.61
$44.28

Technical Indicators

Market Signals
Indicator
VINP
CSTL
Relative Strength Index (RSI) 47.73 67.93
Support Level $9.66 $23.21
Resistance Level $10.88 $26.20
Average True Range (ATR) 0.38 0.87
MACD 0.03 0.47
Stochastic Oscillator 30.66 98.00

Price Performance

Historical Comparison
VINP
CSTL

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: